Acadian Asset Management
PSTV

Acadian Asset Management’s Plus Therapeutics PSTV Stock Holding History

Acadian Asset Management’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-24
Closed -$23K – 2326
2020
Q3 		$23K Hold
24
– – ﹤0.01% 2057
2020
Q2 		$19K Hold
24
– – ﹤0.01% 2137
2020
Q1 		$17K Buy
+24
New +$18.4K ﹤0.01% 1669

Other funds holding PSTV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Acadian Asset Management's PSTV Position: Q4 2020 in Review

Acadian Asset Management sold out of Plus Therapeutics (PSTV) in Q4 2020, closing a stake of 24 shares — an estimated $23K sold.

Acadian Asset Management first reported a position in PSTV in Q1 2020 and held it in 3 quarters. The position peaked at $23K in Q3 2020. 10 funds tracked by Wall St. Rank hold PSTV as of Q4 2020.

  • Acadian Asset Management reported no remaining Plus Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Acadian Asset Management sold 24 Plus Therapeutics shares in Q4 2020, an estimated $23K.
  • Acadian Asset Management first reported a position in Plus Therapeutics in Q1 2020 and held it in 3 quarters.
  • Acadian Asset Management's Plus Therapeutics position peaked at $23K in Q3 2020.
  • 10 funds tracked by Wall St. Rank held Plus Therapeutics as of Q4 2020.

Based on Acadian Asset Management's 13F filing for Q4 2020, filed 11 Feb 2021.